volume 28, issue 6, P698-705 2007
DOI: 10.2500/aap.2007.28.3053
View full text
|
Sign up to set email alerts
|
Share

Abstract: Although immunotherapy has documented short- and long-term benefits with regard to treatment of allergies and asthma as well as reducing development of new allergies and preventing progression of allergic rhinitis to asthma, the age to begin subcutaneous allergen immunotherapy appears established at the age of 5 years by published guidelines for treatment. The rationale for this age limit was examined and found to not reflect actual immunotherapy practice. Reasons for considering a downward revision are explor…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
5
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals